Destiny Pharma (DEST) Share Price, News & Analysis

Company Overview

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 4.18 million shs
• Average Volume: 715,908 shs
• Market Capitalization: £2.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DEST Stock Analysis - Frequently Asked Questions

How were Destiny Pharma's earnings last quarter?

Destiny Pharma plc (LON:DEST) announced its quarterly earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter.

How do I buy shares of Destiny Pharma?

Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Destiny Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Destiny Pharma investors own include 4D pharma (DDDD), Intel (INTC), B&M European Value Retail (BME), BP (BP), Coats Group (COA), genedrive (GDR) and Greencore Group (GNC).

Company Calendar

• Last Earnings: 9/17/2020
• Today: 8/09/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:DEST
• CIK: N/A
• Web: www.destinypharma.com
• Phone: +44-1273-704440
• Fax: N/A
• Employees: 24
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£5.66 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -67.29%
• Return on Assets: -44.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.89
• Quick Ratio: 11.10

Sales & Book Value

• Annual Sales: £135.03 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.69
• Book Value: GBX 10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 95,770,000
• Free Float: N/A
• Market Cap: £2.87 million
• Optionable: Not Optionable
• Beta: 0.22